Esomeprazole/Naproxen Shortage: What Providers and Prescribers Need to Know in 2026

For prescribers managing patients on esomeprazole/naproxen (formerly Vimovo), the current supply situation requires updated clinical guidance. The brand-name Vimovo has been discontinued, and while FDA-approved generic equivalents remain on the market, pharmacy-level availability is inconsistent. This guide covers what you need to know to manage patients on this medication in 2026.

Current Supply Status: What Has Changed

Esomeprazole/naproxen is not classified as an active FDA drug shortage. However, the discontinuation of the original Vimovo brand has created meaningful disruptions at the pharmacy dispensing level. Patients who previously had reliable access to the brand are now being routed to generic versions from Ajanta Pharma USA and Dr. Reddy's Laboratories—manufacturers that may not be stocked at every pharmacy in your patient panel's geographic area.

The practical result is that many patients are reporting inability to fill prescriptions at their usual pharmacy. This is creating unnecessary interruptions in chronic arthritis therapy, with potential clinical consequences including increased disease activity and GI risk if patients are abruptly switching to unprotected NSAID therapy.

Critical Clinical Reminders for Prescribers

Before making any prescribing decisions based on availability, review these key clinical facts:

• Do not substitute with individual naproxen + esomeprazole products. The FDA-approved prescribing information explicitly states that esomeprazole/naproxen combination tablets cannot be substituted with the individual components. The sequential release pharmacokinetics—esomeprazole first, then naproxen—cannot be replicated by administering both simultaneously.
• Not for acute pain. The delayed-release formulation slows naproxen absorption, making this product inappropriate for initial treatment of acute pain. Use only in patients requiring chronic NSAID therapy for arthritis.
• Controlled studies do not exceed 6 months. Long-term use beyond 6 months has not been formally studied in controlled trials. Monitor patients receiving extended therapy appropriately.
• Renal and hepatic restrictions. Avoid in patients with CrCl <30 mL/min (moderate to severe renal impairment) or severe hepatic impairment. Use caution with dose adjustment in mild to moderate hepatic impairment.
• Rilpivirine contraindication. Esomeprazole/naproxen is absolutely contraindicated in patients taking rilpivirine-containing antiretroviral regimens (Complera, Edurant, Odefsey). The PPI component significantly increases gastric pH, reducing rilpivirine absorption and potentially leading to treatment failure and resistance.

Managing Patients Who Cannot Access Esomeprazole/Naproxen

When patients cannot fill their prescription, the clinical decision depends on their specific GI and cardiovascular risk profile:

Option A: Identify Pharmacies That Stock the Generic

For patients who need to stay on this specific regimen, the best approach is finding a pharmacy that carries the generic in stock. medfinder for providers is a service that contacts pharmacies on behalf of your patients to locate which ones can fill the prescription—saving your staff time on prior authorization-related phone calls and pharmacy searches.

38,766+ patients found their medications in stock

38K+

Find Esomeprazole/Naproxen In Stock Today →

Option B: Consider Clinically Appropriate Alternatives

For patients who genuinely cannot access the combination tablet, consider these alternatives based on their risk profile:

• Celecoxib (generic): COX-2 selective NSAID; lower GI risk than naproxen; widely available; preferred for patients with GI risk who have acceptable cardiovascular risk. Widely covered as Tier 1–2 generic on most formularies.
• Diclofenac/Misoprostol (Arthrotec): Alternative fixed-dose NSAID+gastroprotective combination; misoprostol (not a PPI) mechanism; note GI side effects and contraindication in pregnancy.
• Meloxicam + OTC PPI: Preferential COX-2 NSAID with better GI tolerability than non-selective NSAIDs; combining with OTC omeprazole may be acceptable for some patients, though note this is not FDA-approved as a fixed combination.

Insurance and Prior Authorization Considerations

Esomeprazole/naproxen is frequently subject to prior authorization and step therapy requirements. Many payers require documentation of:

• An active diagnosis of OA, RA, AS, or JIA requiring NSAID therapy
• Elevated GI risk (prior GI event, age ≥60, concomitant corticosteroid or anticoagulant use)
• Inadequate response to or contraindication to alternative NSAIDs

Having this documentation readily available in the patient's chart will expedite PA requests. For patients with Medicare Part D, note that this medication often lands in a higher formulary tier—copays may range from $10 to $60+ depending on the plan.

Skip the calls, skip the stress.

Find Esomeprazole/Naproxen In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Monitoring Recommendations for Patients on Esomeprazole/Naproxen

Regardless of availability challenges, patients who are on esomeprazole/naproxen require ongoing monitoring per standard NSAID and PPI guidelines:

• Blood pressure monitoring (NSAIDs can elevate BP)
• Renal function (BMP/CMP annually or more frequently in at-risk patients)
• CBC for signs of GI blood loss in patients at higher GI risk
• Magnesium levels in patients on long-term PPI therapy (>1 year)
• Vitamin B12 for patients on esomeprazole/naproxen longer than 3 years

For a step-by-step guide on helping your patients find the medication, see our provider's guide to helping patients find esomeprazole/naproxen.